Search

More than two decades of research, modelling and collaboration to develop safe and effective RSV immunisations has led to a major Federal Government roll-out of a respiratory syncytial virus (RSV) immunisation program for all pregnant women and newborn babies in 2025.

Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.

The Wal-yan Respiratory Research Centre is seeking expressions of interest from Western Australians to join an Antimicrobial Resistance (AMR) Community Reference Group, to provide vital community perspectives on the research activities into this global health concern. 

Here are some of the most common questions about phage, phage therapy and antimicrobial resistance (AMR).

Although many mothers initiate breastfeeding, supplementation with human-milk substitutes (formula) during the birth hospitalization is common and has been associated with early breastfeeding cessation. Colostrum hand expressed in the last few weeks before birth, known as antenatal colostrum expression (ACE), can be used instead of human-milk substitutes. However, evidence is lacking on the efficacy of ACE on breastfeeding outcomes and in non-diabetic mothers. 

A sub-study is an ‘add-on’ study that helps to answer specific questions within a larger research project. If you decide to participate in the CIRCA DIEM study, you or your child may be invited to take part in one of the CIRCA DIEM sub-studies.

Whooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.

Find answers to frequently asked questions about ORIGINS.

To identify the barriers and facilitators for timely detection and optimal management of otitis media in Aboriginal children in a primary care setting from the perspective of carers of Aboriginal children. 

Addressing the recognized challenges and inequalities in providing high quality healthcare for rare diseases such as children's interstitial lung disease (chILD) requires collaboration across institutional, geographical, discipline, and system boundaries. The Children's Interstitial Lung Disease Respiratory Network of Australia and New Zealand (chILDRANZ) is an example of a clinical network that brings together multidisciplinary health professionals for collaboration, peer learning, and advocacy with the goal of improving the diagnosis and management of this group of rare and ultra-rare conditions.